Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/ALZAMEND-NEURO-INC-123731313/news/Alzamend-Neuro-erhalt-FDA-Bescheid-Study-May-Proceed-fur-eine-klinische-Phase-IIA-Studie-mit-Al0-45402609/?utm_source=whatsapp&utm_medium=social&utm_campaign=share